Page 2 - Prospective Study News Today

Study to evaluate how behavioral and sensor data from wearables and blood tests can be leveraged to help individuals better assess and manage their metabolic healthSECAUCUS, NJ / ACCESSWIRE / January 29, 2024 / Fitbit and Quest Diagnostics (NYSE:DGX), the world's leading provider of diagnostic information services,...

19.01.2024 - 26 different customers representing North America, Asia and Europe33 oral presentations across four consecutive days69 scientific posters will be featured in a virtual exhibition hallTopics span the application of optical genome mapping (OGM) in ...

Study to evaluate how behavioral and sensor data from wearables and blood tests can be leveraged to help individuals better assess and manage their metabolic health SECAUCUS, N.J., Jan. 17, 2024...

In this final episode of OncChats: Reviewing Best Practices in the Surgical Management of Breast Cancer, Gladys Giron, MD, FACS, and Cristina Lopez-Peñalver, MD, shed light on clinical outcomes following surgery of the primary tumor in patients with stage IV breast cancer.

(BPT) - In the quest for radiant-looking skin, we’re constantly on the hunt for the newest cream or silky serum, and trendy treatments don’t always deliver the results we hoped

PARIS (Reuters) -French artificial heart maker Carmat said on Monday it had implanted seven of its Aeson devices as part of a clinical study in Paris, sending its shares up almost 8%. “This ramp-up is the result of growing experience in patient selection and attests to the steep learning curve of the surgical procedure,” Professor Christian Latremouille, director of surgical affairs at Carmat, said in a press release. The clinical study, called EFICAS, is a prospective study des...

PARIS, October 23, 2023--Regulatory News: CARMAT (FR0010907956, ALCAR), designer and developer of the world's most advanced total artificial heart, aimed at providing a therapeutic alternative for patients suffering from advanced biventricular heart failure (the "Company" or "CARMAT"), announces that it has presented its progress on the EFICAS clinical trial at the 36th "Journées de La Pitié" national conference on heart and lung transplantation and c...

Lunit (KRX:328130.KQ), a leading provider of AI-powered solutions for cancer diagnostics and therapeutics, is spearheading a transformative change in breast cancer screening, bolstered by groundbreaking findings from a prospective study led by Dr. Fredrik Strand at the Karolinska Institutet, Sweden, involving over 50,000 women.

NeurAxis Inc (NYSE: NRXS) announced the publication of a Prospective study evaluating the efficacy of IB-Stim in children featured in the September 2023 Frontiers in Pain Research. The publication investigated changes in gastrointestinal symptoms and quality of life in 31 adolescent patients aged 11 – 18 years with functional abdominal pain disorders (FAPDs) before and after treatment with IB-Stim. Also Read: EXCLUSIVE: Small MedTech Firm NeurAxis Targets $2B Market With Post-Concussion T...

NeurAxis Inc (NYSE: NRXS) highlighted A Prospective Study on the Effect of Auricular Percutaneous Electrical Nerve Field Stimulation (PENFS) in Patients with Post-Concussion Syndrome (PCS), a randomized, double-blind, placebo-controlled trial to evaluate the efficacy of IB-Stim in children with post-conc